InflaRx (IFRX) Stock Price, News & Analysis

Company Overview

InflaRx NV is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic antibodies targeting components of the innate immune system. The company’s lead program is vilobelimab (IFX-1), a monoclonal antibody that selectively inhibits the complement factor C5a, a potent driver of inflammation. InflaRx is advancing vilobelimab in multiple indications, including hidradenitis suppurativa, paroxysmal nocturnal hemoglobinuria and other rare and severe inflammatory diseases, with both ongoing and planned clinical trials.

Founded in 2007 and headquartered in Jena, Germany, InflaRx maintains operational offices in the United States to support its North American development and regulatory activities. The company has established strategic collaborations for manufacturing and clinical research in Europe and North America, ensuring access to state-of-the-art facilities and patient populations. InflaRx completed its initial public offering on the NASDAQ stock exchange in 2019 to accelerate its pipeline advancement and expand global clinical programs.

Under the leadership of Chief Executive Officer Jan Schmidt, InflaRx is led by a management team with extensive experience in immunology, drug development and regulatory affairs. The company’s board and scientific advisory group include industry veterans from biotechnology and pharmaceutical backgrounds who guide strategy and clinical program design. InflaRx remains committed to translating its complement-modulating platform into novel therapies that address unmet needs in inflammatory and autoimmune diseases worldwide.

Key Stats

• Today's Range: $0.83 to $0.88
• 50-Day Range: $0.73 to $1.85
• 52-Week Range: $0.71 to $2.82
• Volume: 177,355 shs
• Average Volume: 308,674 shs
• Market Capitalization: $58.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.60
• Consensus Rating: Buy

InflaRx Stock Analysis - MarketRank™

InflaRx scored higher than 56% of companies evaluated by MarketBeat, and ranked 496th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

InflaRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

InflaRx has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for InflaRx are expected to decrease in the coming year, from ($1.04) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InflaRx is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InflaRx is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InflaRx has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.21% of the float of InflaRx has been sold short.

Short Interest Ratio / Days to Cover

InflaRx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InflaRx has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InflaRx does not currently pay a dividend.

Dividend Growth

InflaRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.21% of the float of InflaRx has been sold short.

Short Interest Ratio / Days to Cover

InflaRx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InflaRx has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.65

News Sentiment

InflaRx has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for InflaRx this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InflaRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IFRX Stock Analysis - Frequently Asked Questions

How have IFRX shares performed this year?

InflaRx's stock was trading at $2.47 at the start of the year. Since then, IFRX stock has decreased by 65.0% and is now trading at $0.8640.

How were InflaRx's earnings last quarter?

InflaRx N.V. (NASDAQ:IFRX) issued its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. The business had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.03 million.

When did InflaRx IPO?

InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IFRX
• CIK: 1708688
• Web: www.inflarx.de
• Phone: 493641508180
• Fax: 49-36-4150-8181
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InflaRx: $6.60
• High Price Target: $10.00
• Low Price Target: $2.00
• Potential Upside/Downside: +663.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.85 million
• Net Margins: N/A
• Pretax Margin: -33,646.85%
• Return on Equity: -64.17%
• Return on Assets: -53.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.28
• Quick Ratio: 4.86

Sales & Book Value

• Annual Sales: $180 thousand
• Price / Sales: 322.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.13 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 67,130,000
• Free Float: 56,190,000
• Market Cap: $58.00 million
• Optionable: Optionable
• Beta: 1.29